MDCX Medicus Pharma Ltd
Price Chart
Executive Summary
Medicus Pharma announced positive dose-response results from an expanded analysis of its Phase 2 SKNJCT-003 study for Doxorubicin Microneedle Array (D-MNA) in nodular basal cell carcinoma. The 200µg cohort showed 55% histological clearance at Day 57 vs. 29% for device-only control, with a favorable safety profile. The data strengthens the registrational path ahead of End-of-Phase 2 discussions with the FDA, but the company has a $11M market cap and no approved products, making this an early-stage binary event.
Actionable Insight
The positive dose-response data de-risks the program but the stock has a history of extreme volatility (avg T+20 -29.5% on prior reports). Monitor for FDA EOP2 meeting announcement and potential partnership/offering news. Given the low market cap and binary nature, position sizing should be minimal.
Key Facts
- Expanded analysis of 69 patients with nodular BCC showed 200µg D-MNA achieved 55% histological clearance at Day 57 vs. 29% for device-only control.
- Clear dose-response relationship demonstrated, with 200µg cohort showing progressive improvement from Day 29 to Day 57.
- No drug-related serious adverse events or systemic doxorubicin toxicity reported; predominantly mild localized reactions.
- Company plans to advance toward End-of-Phase 2 (EOP2) discussions with FDA for registrational path.
- Market cap is ~$11M with no approved products; stock has high volatility and negative historical performance (avg T+20 return -29.5% on prior reports).
Financial Impact
No financial data provided; company is pre-revenue with ~$2B market opportunity for BCC/Gorlin Syndrome.
Risk Factors
- FDA may not agree with registrational path or require additional studies.
- Company has no approved products and limited cash runway (not disclosed).
- Historical stock performance shows severe negative returns after positive news (avg T+20 -29.5%).
- Competition from existing BCC treatments (surgery, topical therapies).
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288692 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 14, 2026
29d ago
|
Press Release
| $0.3010 $0.3000 | ▲ +0.33% | ▲ +1.30% | $0.3380 (−12.29%) |
|
May 6, 2026
5w ago
|
Press Release
| $0.3330 $0.3150 | ▼ −5.41% | ▼ −6.54% | $0.3380 (+1.50%) |
|
Apr 6, 2026
9w ago
|
Press Release
| $0.4910 $0.4020 | ▼ −18.13% | ▼ −22.26% | $0.3380 (−31.16%) |
|
Apr 1, 2026
10w ago
|
Press Release
| $0.4200 $0.4420 | ▲ +5.24% | ▲ +1.47% | $0.3380 (−19.52%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $0.5240 $0.5000 | ▼ −4.58% | ▼ −2.54% | $0.3380 (−35.50%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $0.5200 $0.5240 | ▲ +0.77% | ▲ +2.12% | $0.3380 (−35.00%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $0.6780 $0.5000 | ▼ −26.25% | ▼ −24.02% | $0.3380 (−50.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access